Home > Insider Trading > Filing (0001209191-22-063009)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1620463	Athira Pharma Inc.	ATHA	Biological Products, (No Disgnostic Substances) (2836)	453368487

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1822241	Glenna Mileson	C/O Athira Pharma, Inc. 18706 North Creek Parkway, Suite 104 Bothell WA 98011	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-11-18	763	$2.74	109,930	No	5	A	Direct
Common Stock	Acquisiton	2022-12-28	50,000	$2.85	159,930	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	A	Direct
No	4	P	Direct

Footnotes

The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c).
The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022.
In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022.
The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.93 to $2.98,inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, fullinformation regarding the number of shares purchased at each separate price within such range.